PCM
INM icon

Penserra Capital Management’s InMed Pharmaceuticals INM Stock Holding History

Penserra Capital Management’s Portfolio INM Stock Details INM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-40
Closed -$49K – 1491
2021
Q2 		$49K Buy
+40
New +$61.9K ﹤0.01% 1002

Other funds holding INM

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return
FF
FourThought Financial Venice, Florida $677M AUM 12.73% 1-Year Est. Return
NWM
Navigation Wealth Management Fort Collins, Colorado $72.6M AUM 19.86% 1-Year Est. Return

Penserra Capital Management's INM Position: Q3 2021 in Review

Penserra Capital Management sold out of InMed Pharmaceuticals (INM) in Q3 2021, closing a stake of 40 shares — an estimated $49K sold.

Penserra Capital Management first reported a position in INM in Q2 2021 and held it in 1 quarter. The position peaked at $49K in Q2 2021. 11 funds tracked by Wall St. Rank hold INM as of Q3 2021.

  • Penserra Capital Management reported no remaining InMed Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Penserra Capital Management sold 40 InMed Pharmaceuticals shares in Q3 2021, an estimated $49K.
  • Penserra Capital Management first reported a position in InMed Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Penserra Capital Management's InMed Pharmaceuticals position peaked at $49K in Q2 2021.
  • 11 funds tracked by Wall St. Rank held InMed Pharmaceuticals as of Q3 2021.

Based on Penserra Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.